STOCK TITAN
  1. Home
  2. Sec-filings
  3. SOPH
  4. [Form 4] SOPHiA GENETICS SA Insider Trading Activity

SOPHiA GENETICS (SOPH) CMO pre-planned tax-related sale of 8,125 shares

Filing Impact
(Neutral)
Filing Sentiment
(Negative)
Form Type
4

Rhea-AI Filing Summary

SOPHiA GENETICS SA Chief Medical Officer Philippe Menu reported small open-market sales of Ordinary Shares mainly to cover taxes from recent equity vesting. Across three transactions on April 10 and April 13, 2026, he sold a total of 8,125 shares at weighted-average prices around $4.68–$4.76 per share. The filing states these sales were made to satisfy tax withholding obligations tied to restricted stock units that vested on April 2 and 3, 2026 and were executed under a pre-established Rule 10b5-1(c) trading plan. After these transactions, Menu continues to hold 268,596 Ordinary Shares directly.

Positive

  • None.

Negative

  • None.

Insights

Routine, pre-planned tax-related sales with substantial holdings retained.

The Chief Medical Officer, Philippe Menu, conducted three open-market sales totaling 8,125 Ordinary Shares at prices around $4.68–$4.76 per share. The filing explains these sales were to satisfy tax withholding obligations from restricted stock unit vesting.

The sales were executed under a pre-established Rule 10b5-1(c) trading plan and are described as non-discretionary. This structure typically indicates routine, pre-planned liquidity rather than opportunistic trading. Following the transactions, Menu still directly holds 268,596 shares, suggesting only a small portion of his position was sold.

From an investor’s perspective, the transactions appear administrative and compensation-related rather than a directional signal about the company’s prospects. The absence of derivative positions in the derivative summary reinforces that this filing mainly reflects equity from prior grants rather than option exercises.

Insider Menu Philippe
Role Chief Medical Officer
Sold 8,125 shs ($38K)
Type Security Shares Price Value
Sale Ordinary Shares 1,000 $4.7642 $5K
Sale Ordinary Shares 3,400 $4.7642 $16K
Sale Ordinary Shares 3,725 $4.6822 $17K
Holdings After Transaction: Ordinary Shares — 271,996 shares (Direct)
Footnotes (1)
  1. Represents shares sold by the Reporting Person in the open market to satisfy tax withholding obligations arising in connection with the vesting of restricted stock units on April 2 and 3, 2026. These sales were effected pursuant to a pre-established Rule 10b5-1(c) trading plan adopted by the Reporting Person and do not represent discretionary trades. The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $4.61 to $4.77, inclusive. The Reporting Person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $4.62 to $4.88, inclusive. The Reporting Person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Transaction made pursuant to duly adopted trading plan under Rule 10b5-1(c).
Total shares sold 8,125 shares Open-market sales on April 10 and 13, 2026
Sale price April 10 $4.6822 per share Weighted-average price for 3,725 shares sold
Sale price April 13 $4.7642 per share Weighted-average price for 1,000 and 3,400 shares sold
Price range footnote (first sale set) $4.61–$4.77 Multiple transactions within this range per footnote
Price range footnote (second sale set) $4.62–$4.88 Multiple transactions within this range per footnote
Shares held after transactions 268,596 shares Direct ownership after April 13, 2026 sales
Rule 10b5-1(c) trading plan regulatory
"These sales were effected pursuant to a pre-established Rule 10b5-1(c) trading plan adopted by the Reporting Person"
A Rule 10b5-1(c) trading plan is a legally defined, pre-set schedule that lets company insiders automatically buy or sell stock at specified times or under set formulas when they are not in possession of undisclosed, sensitive information. Think of it like an automatic payment plan for trades: because the instructions are written in advance, trades under the plan help protect insiders from allegations of trading on secret information and give investors clearer expectations about when insiders will transact, which can affect liquidity and perceived transparency.
restricted stock units financial
"tax withholding obligations arising in connection with the vesting of restricted stock units on April 2 and 3, 2026"
Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.
weighted average price financial
"The price reported in Column 4 is a weighted average price."
Weighted average price is the average price of a security where each trade or component is counted according to its size, so bigger trades pull the average more than smaller ones. Think of it like calculating the average cost of a grocery haul where items you bought more of have greater influence on the final per-item cost. Investors use it to understand the true average price paid or received, judge execution quality, and compare trading performance against market movement.
open market financial
"Represents shares sold by the Reporting Person in the open market to satisfy tax withholding obligations"
An open market is a system where buying and selling of goods, services, or financial assets happen freely without restrictions or special controls. For investors, it means they can trade assets easily and quickly, which helps determine fair prices based on supply and demand. This environment encourages transparency and competition, making it easier to buy or sell with confidence.
non-discretionary trades financial
"do not represent discretionary trades."
Form 4 Insider Transactions: What Each Field Means →
SEC Form 4
FORM 4UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number:3235-0287
Estimated average burden
hours per response:0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
X
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Menu Philippe
(Last)(First)(Middle)
C/O SOPHIA GENETICS SA
LA PIECE 12
(Street)
ROLLE1180
(City)(State)(Zip)
SWITZERLAND
(Country)		2. Issuer Name and Ticker or Trading Symbol
SOPHiA GENETICS SA [ SOPH ] 		5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
Director10% Owner
XOfficer (give title below)Other (specify below)
Chief Medical Officer
2a. Foreign Trading Symbol
3. Date of Earliest Transaction (Month/Day/Year)
04/10/2026		6. Individual or Joint/Group Filing (Check Applicable Line)
XForm filed by One Reporting Person
Form filed by More than One Reporting Person
4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year)2A. Deemed Execution Date, if any (Month/Day/Year)3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeVAmount(A) or (D)Price
Ordinary Shares04/10/2026S3,725(1)D$4.6822(2)272,996D
Ordinary Shares04/13/2026S1,000(1)D$4.7642(3)271,996D
Ordinary Shares04/13/2026S3,400(4)D$4.7642(3)268,596D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year)3A. Deemed Execution Date, if any (Month/Day/Year)4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year)7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeV(A)(D)Date ExercisableExpiration DateTitleAmount or Number of Shares
Explanation of Responses:
1. Represents shares sold by the Reporting Person in the open market to satisfy tax withholding obligations arising in connection with the vesting of restricted stock units on April 2 and 3, 2026. These sales were effected pursuant to a pre-established Rule 10b5-1(c) trading plan adopted by the Reporting Person and do not represent discretionary trades.
2. The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $4.61 to $4.77, inclusive. The Reporting Person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
3. The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $4.62 to $4.88, inclusive. The Reporting Person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
4. Transaction made pursuant to duly adopted trading plan under Rule 10b5-1(c).
Remarks:
/s/ Elimara Brunetto as Attorney-in-fact for Philippe Menu04/14/2026
** Signature of Reporting PersonDate
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR

FAQ

What insider transaction did SOPHiA GENETICS (SOPH) report for Philippe Menu?

SOPHiA GENETICS reported that Chief Medical Officer Philippe Menu sold 8,125 Ordinary Shares. These were three open-market sales on April 10 and 13, 2026 at weighted-average prices around $4.68–$4.76 per share, disclosed in a Form 4 insider filing.

Why did SOPHiA GENETICS CMO Philippe Menu sell 8,125 shares of SOPH?

The filing states Menu’s 8,125-share sales were made to satisfy tax withholding obligations from restricted stock units that vested on April 2 and 3, 2026. The transactions are described as administrative, tied to equity compensation rather than discretionary trading decisions.

Were Philippe Menu’s SOPHiA GENETICS share sales made under a Rule 10b5-1 plan?

Yes. The Form 4 explains these sales were executed under a pre-established Rule 10b5-1(c) trading plan. Such plans are adopted in advance and automate transactions, indicating the timing of these tax-related sales was pre-planned and not based on short-term market views.

How many SOPHiA GENETICS shares does Philippe Menu hold after the reported sales?

After the reported transactions, Chief Medical Officer Philippe Menu directly holds 268,596 Ordinary Shares of SOPHiA GENETICS SA. This remaining stake shows that the 8,125 shares sold for tax withholding represent only a small portion of his overall shareholdings.

What prices did Philippe Menu receive for his SOPHiA GENETICS share sales?

The filing reports weighted-average sale prices of $4.6822 per share on April 10, 2026 and $4.7642 per share on April 13, 2026. Footnotes note individual trades occurred in ranges of $4.61–$4.77 and $4.62–$4.88 per share, respectively.

Do Philippe Menu’s SOPHiA GENETICS share sales signal a change in his investment view?

The Form 4 characterizes these transactions as non-discretionary sales to cover tax withholding from restricted stock unit vesting, under a pre-established Rule 10b5-1(c) plan. This framing suggests the activity is largely administrative, not a deliberate change in his investment outlook.